Mouse models of high-risk neuroblastoma

被引:0
作者
Alvin Kamili
Caroline Atkinson
Toby N. Trahair
Jamie I. Fletcher
机构
[1] UNSW Sydney,Children’s Cancer Institute Australia, Lowy Cancer Research Centre
[2] UNSW Sydney,School of Women’s and Children’s Health
[3] Sydney Children’s Hospital,Kids Cancer Centre
来源
Cancer and Metastasis Reviews | 2020年 / 39卷
关键词
Neuroblastoma; GEMM; PDX; Mouse model; Pre-clinical testing;
D O I
暂无
中图分类号
学科分类号
摘要
Informative and realistic mouse models of high-risk neuroblastoma are central to understanding mechanisms of tumour initiation, progression, and metastasis. They also play vital roles in validating tumour drivers and drug targets, as platforms for assessment of new therapies and in the generation of drug sensitivity data that can inform treatment decisions for individual patients. This review will describe genetically engineered mouse models of specific subsets of high-risk neuroblastoma, the development of patient-derived xenograft models that more broadly represent the diversity and heterogeneity of the disease, and models of primary and metastatic disease. We discuss the research applications, advantages, and limitations of each model type, the importance of model repositories and data standards for supporting reproducible, high-quality research, and potential future directions for neuroblastoma mouse models.
引用
收藏
页码:261 / 274
页数:13
相关论文
共 50 条
  • [11] HIGH-RISK NEUROBLASTOMA: A Therapy in Evolution
    Fong, Abraham
    Park, Julie R.
    PEDIATRIC HEMATOLOGY AND ONCOLOGY, 2009, 26 (08) : 539 - 548
  • [12] Telomere maintenance is pivotal for high-risk neuroblastoma
    Hertwig, Falk
    Peifer, Martin
    Fischer, Matthias
    CELL CYCLE, 2016, 15 (03) : 311 - 312
  • [13] Prolonged Isotretinoin in Ultra High-Risk Neuroblastoma
    Cash, Thomas
    Alazraki, Adina
    Qayed, Muna
    Katzenstein, Howard M.
    JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY, 2017, 39 (01) : E33 - E35
  • [14] Pharmacologic Management of High-Risk Neuroblastoma in Children
    Veena R. Ganeshan
    Nina F. Schor
    Pediatric Drugs, 2011, 13 : 245 - 255
  • [15] Molecular profiling of high-risk neuroblastoma by cDNA array
    Sardi, I
    Tintori, V
    Marchi, C
    Veltroni, M
    Lippi, A
    Tucci, F
    Tamburini, A
    Bernini, G
    Faulkner, L
    INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE, 2002, 9 (05) : 541 - 545
  • [16] Intraoperative radiation therapy for high-risk pediatric neuroblastoma
    Haas-Kogan, DA
    Fisch, BM
    Wara, WM
    Swift, PS
    Farmer, DL
    Harrison, MR
    Albanese, C
    Weinberg, V
    Matthay, KK
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2000, 47 (04): : 985 - 992
  • [17] Value of surgical resection in children with high-risk neuroblastoma
    Englum, Brian R.
    Rialon, Kristy L.
    Speicher, Paul J.
    Gulack, Brian
    Driscoll, Timothy A.
    Kreissman, Susan G.
    Rice, Henry E.
    PEDIATRIC BLOOD & CANCER, 2015, 62 (09) : 1529 - 1535
  • [18] Ototoxicity: a worrying problem for survivors of high-risk neuroblastoma
    Castel, Victoria
    Berlanga, Pablo
    TRANSLATIONAL CANCER RESEARCH, 2014, 3 (06) : 521 - 524
  • [19] Venous Thrombosis and Procoagulant Factors in High-risk Neuroblastoma
    Schiavetti, Amalia
    Foco, Micaela
    Chiriaco, Damiano
    Iacobini, Metello
    Varrasso, Giulia
    Ingrosso, Annapaola
    Conti, Laura
    JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY, 2010, 32 (02) : 93 - 96
  • [20] Ovarian function in female survivors of high-risk neuroblastoma
    Jimenez-Kurlander, Lauren
    DeRosa, Amelia
    Kostrzewa, Caroline E.
    Moskowitz, Chaya S.
    Bogardus, Kimberly
    Antal, Zoltan
    Wolden, Suzanne
    La Quaglia, Michael P.
    Basu, Ellen M.
    Cardenas, Fiorella Iglesias
    Kramer, Kim
    Kushner, Brian H.
    Cheung, Nai-Kong V.
    Modak, Shakeel
    Friedman, Danielle Novetsky
    PEDIATRIC BLOOD & CANCER, 2024, 71 (09)